Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy

Published:2014-12-23 Issue:4 Volume:15 Page:354-362
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Maus M K H,Hanna D L,Stephens C L,Astrow S H,Yang D,Grimminger P P,Loupakis F,Hsiang J H,Zeger G,Wakatsuki T,Barzi A,Lenz H-J

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/tpj201473.pdf

Reference76 articles.

1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626–1634.

2. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535–1546.

3. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992–3995.

4. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011–2019.

5. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755–1762.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The survival outcome differs between left-sided colon cancer and middle/low rectal cancer after colorectal hepatic metastasectomy;Journal of Gastrointestinal Surgery;2024-08

2. Risk factors for synchronous high-risk polyps in patients with colorectal cancer;Frontiers in Surgery;2024-06-24

3. Risk Factors for Synchronous High-risk Polyps in Patients with Colorectal Cancer;2024-01-15

4. mRNA of the <i>OY-TES-1</i> gene in peripheral blood and tumors in colorectal cancer;Russian Journal of Biotherapy;2023-10-17

5. Colonic Fluid and Electrolyte Transport 2022: An Update;Cells;2022-05-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3